A Phase I/II Dose Finding Trial of the Intravenous Injection of CV787, a Prostate-Specific Antigen Cytolytic Adenovirus, in Patients With Hormone Refractory Metastatic Prostate Cancer


Phase 1/Phase 2

Not Enrolling

Prostate Cancer

Thank you

Trial Information

A Phase I/II Dose Finding Trial of the Intravenous Injection of CV787, a Prostate-Specific Antigen Cytolytic Adenovirus, in Patients With Hormone Refractory Metastatic Prostate Cancer

Inclusion Criteria

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the safety, tolerability, and the maximum tolerated dose of CG7870 when administered intravenously to patients with progressive metastatic hormone refractory prostate cancer

Authority:

United States: Food and Drug Administration

Study ID:

CV787-9902

NCT ID:

NCT00116155

Start Date:

Completion Date:

Related Keywords:

  • Prostate Cancer
  • Hormone Refractory Metastatic Prostate Cancer
  • Prostatic Neoplasms

Name

Location